NeuroBridge Competitors

Neuralink is a neurotechnology company building a generalized input/output platform for the brain. Our work has the potential to restore autonomy to those with unmet medical needs and fundamentally transform how humans interact with the world. Our core technology is an implantable brain-computer interface with ultra-thin, flexible electrode threads placed precisely by a surgical robot, enabling high-bandwidth, bidirectional interaction with neural signals. We’ve received multiple FDA Breakthrough Device designations and are conducting clinical trials around the world. Trial participants are exploring how our implant could enhance their daily lives — controlling digital devices like computers and smartphones, operating physical devices like robotic arms and wheelchairs, and translating thought directly into speech and text. Developing brain-computer interfaces is an interdisciplinary challenge, and we’re looking for exceptional talent across engineering, science, and operations. Explore opportunities to contribute to our mission at neuralink.com/careers.

BrainCo’s leadership draws on deep experience in neuroscience research and expertise in education to deliver entirely new applications of brainwave technology in the education, wellness, and research spaces. We’ve learned important lessons as we’ve grown from a small team in an apartment basement to over 100 employees in 4 offices around the world. Since 2015 we’ve been working on providing the best experience possible for our customers and we’re here to share our progress and innovations with you.

NervGen (NASDAQ: NGEN) is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. The Company’s mission is to transform the lives of individuals living with SCI by enabling the nervous system to repair itself. NervGen’s lead therapeutic candidate, NVG-291, is a subcutaneously administered, neuroreparative peptide designed to target the inhibitory CSPG-PTPσ pathway. NVG-291 is the first pharmacologic candidate to improve function, independence, and quality of life in chronic tetraplegia, as demonstrated in the Phase 1b/2a CONNECT SCI study. NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency for the treatment of SCI. Through NVG-291 and the Company’s next-generation candidate, NVG-300, NervGen is pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions with significant unmet medical need.